The current P/E ratio of BMY cannot be calculated, as the latest EPS of -$4.41 is negative. The last PE ratio of Bristol Myers Squibb, recorded in December 2023, was 13.22.
The PE ratio of Bristol Myers Squibb has averaged 43.98 over the last ten years. Analyzing the last ten years, BMY's PE ratio reached its highest point in the Jun 2018 quarter at 221.36, when the price was $55.34 and the EPS was $0.25. The lowest point was recorded in the Jun 2019 quarter, when it reached 11.93 with a price of $45.35 and an EPS of $3.8.
Maximum annual increase: 358.93% in 2017
Maximum annual decrease: -82.81% in 2018
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | N/A | N/A | $56.56 | -$4.41 |
2023 | 13.22 | -45.44% | $51.31 | $3.88 |
2022 | 24.23 | 22.44% | $71.95 | $2.97 |
2021 | 19.79 | N/A | $62.35 | $3.15 |
2020 | N/A | N/A | $62.03 | -$3.99 |
2019 | 31.78 | 84.02% | $64.19 | $2.02 |
2018 | 17.27 | -82.81% | $51.98 | $3.01 |
2017 | 100.46 | 358.93% | $61.28 | $0.61 |
2016 | 21.89 | -70.09% | $58.44 | $2.67 |
2015 | 73.18 | 49.99% | $68.79 | $0.94 |
2014 | 48.79 | 43.21% | $59.03 | $1.21 |
2013 | 34.07 | 22.33% | $53.15 | $1.56 |
2012 | 27.85 | 72.23% | $32.59 | $1.17 |
2011 | 16.17 | 9.93% | $35.24 | $2.18 |
2010 | 14.71 | 211.65% | $26.48 | $1.8 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | N/A | N/A | $56.56 | -$4.41 |
Sep 2024 | N/A | N/A | $51.74 | -$3.59 |
Jun 2024 | N/A | N/A | $41.53 | -$3.25 |
Mar 2024 | N/A | N/A | $54.23 | -$3.09 |
Dec 2023 | 13.22 | -9.58% | $51.31 | $3.88 |
Sep 2023 | 14.62 | -13.59% | $58.04 | $3.97 |
Jun 2023 | 16.92 | -15.53% | $63.95 | $3.78 |
Mar 2023 | 20.03 | -17.33% | $69.31 | $3.46 |
Dec 2022 | 24.23 | 5.3% | $71.95 | $2.97 |
Sep 2022 | 23.01 | -9.16% | $71.09 | $3.09 |
Jun 2022 | 25.33 | -1.48% | $77 | $3.04 |
Mar 2022 | 25.71 | 29.91% | $73.03 | $2.84 |
Dec 2021 | 19.79 | N/A | $62.35 | $3.15 |
Sep 2021 | N/A | N/A | $59.17 | -$2.37 |
Jun 2021 | N/A | N/A | $66.82 | -$2.24 |
Stock name | PE ratio | Market cap |
---|---|---|
MRK Merck & Co Inc | 12.89 | $220.07B |
ABT Abbott Laboratories | 17.17 | $228.39B |
PFE Pfizer Inc | 17.28 | $139.08B |
NVS Novartis AG | 18.52 | $216.49B |
JNJ Johnson & Johnson | 26.24 | $368.97B |
AZN Astrazeneca plc | 31.98 | $225.14B |
AMGN Amgen Inc | 40.28 | $164.88B |
LLY ELI LILLY & Co | 68.47 | $763.49B |
ABBV AbbVie Inc | 85.95 | $364.14B |
BMY Bristol Myers Squibb Co | N/A | $120.85B |
The current price to earnings ratio of BMY cannot be determined, as its EPS of -$4.41 is negative.
The 3-year average PE ratio for BMY stock is 19.62.
The 5-year average PE ratio for BMY stock is 20.32.
Over the last ten years, the quarterly PE ratio reached its highest level at 221.36 in the Jun 2018 quarter.
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.